Bombesin Receptor Subtype-3 in Human Diseases

Arch Med Res. 2019 Oct;50(7):463-467. doi: 10.1016/j.arcmed.2019.11.004. Epub 2020 Jan 5.

Abstract

This review summarizes the recent findings of the roles of bombesin receptor subtype-3 (BRS-3) in various patho-physiological conditions. Studies have demonstrated that two mammalians bombesin-like peptides, GRP and NMB, exhibit a large range of functions by binding to three receptors. Knockout studies showed that the mice BRS-3 has important effects on tumor growth, energy homeostasis, glucose regulation, satiety, and lung development (1,7). BRS-3 is an orphan receptor whose natural ligand is unknown. However, several agonists and antagonists have been synthesized which facilitate its characterization, (D-Tyr6, β-Ala11, Phe13, Nle14) Bn-(6-14) and MK-5046 are agonists, whereas ML-18 and Bantag-1 are antagonists. With the development of several selective, high-affinity BRS-3 agonists and antagonists, recent studies provided some insights into the biological effects of BRS-3 in several disease states including lung cancer, obesity, diabetes mellitus, asthma, and kidney diseases.

Keywords: Asthma; Bombesin receptor subtype-3; Diabetes mellitus; Kidney diseases; Lung cancer; Obesity.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Disease / genetics*
  • Humans
  • Mice
  • Mice, Knockout
  • Receptors, Bombesin / genetics*

Substances

  • Receptors, Bombesin
  • bombesin receptor subtype 3